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A B S T R A C T
This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:
Primary objective
To summarise the predictive performance of prognostic models developed to predict the risk of relapse, recurrence, sustained remission
or recovery in adults with depression who meet criteria for remission.
Secondary objectives
• To describe the characteristics of models identified, including predictors and method of derivation (e.g. regression, machine learning,
neural networks etc.).
• To review the net benefit of identified models, where this has been reported.
• To summarise the value of updating or modifying an existing prognostic model or identify whether the development of a novel prog-
nostic model to predict relapse and recurrence in depression is required. We will make this decision through discussion involving the
whole team and will be guided by risk of bias assessment and applicability of methods as well as predictive performance.
Investigation of sources of heterogeneity between studies
We anticipate between-study heterogeneity in model performance. Sources of heterogeneity in this case are likely to relate to popula-
tion/case mix (e.g. age of participants and multimorbidity), study setting of models (e.g. differences between models developed in primary
and secondary care settings), study design (e.g. follow-up time, source of data, outcome definition and sample size). All of these could
prove to be significant sources of heterogeneity in this review and we will take them into account in the event that a meta-analysis is
undertaken.
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B A C K G R O U N D
Description of the condition
Depression is the leading cause of disability worldwide (WHO 2018).
After treatment of the first episode of depression, approximately
half of patients will relapse, and this risk increases for every subse-
quent episode (to 70% after a second episode and 90% after a third
episode) (Ali 2017). A recent study showed that of those who re-
lapse, the majority (79%) do so within the first six months (Ali 2017).
Relapse in the context of depression has been defined as the re-
emergence of depressive symptoms following some level of remis-
sion but preceding recovery and is distinguished in the literature
from recurrence (the onset of a new episode of depression fol-
lowing an extended period of remission) (Beshai 2011). Remission
and recovery are similarly differentiated, with remission meaning
asymptomatic but still ‘in episode’ and recovery being defined as
resolution of the underlying episode (usually after 6 to 12 months)
(Bockting 2015). ‘Response’ is often used to describe some im-
provement but not fully well (i.e. not yet achieving remission).
Description of the prognostic models
Prognosis refers to future outcomes given a particular baseline con-
dition or disease. The Prognosis Research Strategy (PROGRESS)
framework was developed in 2013 (PROGRESS 2013), and de-
scribed four main categories of prognosis research: overall prog-
nosis; prognostic factor research; prognostic model research; and
predictors of treatment effect. This review will focus on prognostic
model research (Riley 2019). A prognostic factor is a variable that is
associated with an increased risk of a future outcome. A multivari-
able prognostic model is a way (usually a mathematical equation)
of combining information about multiple prognostic factors (hence
multivariable) to produce an estimate of an individual’s risk of de-
veloping a particular outcome in the future (Riley 2019).
We will review the predictive performance, format, included pre-
dictors and net benefit of all existing prognostic models developed
to predict relapse or recurrence of depression. Sustained remission
can be thought of as the inverse, or opposite, of relapse; and re-
covery as the inverse of recurrence. Both of these hold potential-
ly valuable prognostic information pertinent to relapse risk predic-
tion models. We are interested, therefore, in multivariable prog-
nostic models that have been developed to predict an individual’s
risk of relapse, recurrence, sustained remission or recovery in de-
pression. The starting point for prognostication is when a patient
with depression has responded to treatment and meets criteria for
remission. The included models must have been developed with
the intention of providing individualised risk predictions and we
will exclude papers reporting multivariable models not intended
for this purpose.
Health outcomes
Relapse or recurrence of depression, and sustained remission or re-
covery from depression, all as defined by authors of individual stud-
ies.
Why it is important to do this review
There is evidence to suggest that the severity of depression and
resistance to treatment increases with each successive episode
(Kendler 2000), so there are potential benefits of intervening to pre-
vent relapse. Reliable prediction of individuals’ risk of relapse and
recurrence would enable more efficient allocation, in practice, of
interventions to prevent relapse. The strongest prognostic factors
associated with increased risk of relapse and recurrence of depres-
sion are childhood maltreatment, history of recurrent depression
and presence of residual symptoms. Comorbid anxiety, rumina-
tion, neuroticism and age of onset have also been associated with
increased risk of relapse or recurrence (Buckman 2018).
While a single prognostic factor can give an estimate of overall
prognosis, combining several prognostic factors within the same
model usually results in better individualised risk predictions. A
systematic review of existing prognostic models for the intended
population, outcome and setting and their performance is a recom-
mended first step in the development of a novel prognostic model.
If an existing model performs satisfactorily, adjusting this for the
intended population and externally validating the model is likely to
be a better use of resources than developing a model from the be-
ginning (Riley 2019).
The predictive performance of a prognostic model can be mea-
sured in several ways which include: overall measures of model
fit (for example R2, which measures explained variation for mod-
els with continuous outcomes, or generalizations of R2 for models
with binary or time-to-event outcomes); calibration (which mea-
sures the extent to which risk predictions and observed outcomes
are in agreement); and discrimination (the model’s ability to sepa-
rate patients who develop the outcome of interest and those who
do not, usually measured using the Concordance (C-) statistic or
area under the curve (AUC). A C-statistic of 1 indicates that a model
has perfect discrimination while a C-statistic of 0.5 means that the
model performs no better than chance) (Riley 2019).
There have been some attempts to derive and validate prognos-
tic models to predict depression-related outcomes. Existing prog-
nostic models for depression outcomes include a model (the De-
pression Outcomes Calculator-Six Items, (DOC-6©)) to predict re-
mission (C-statistic (AUC) of 0.62 (95% CI 0.57 to 0.66)) or persistent
depressive symptoms (C-statistic (AUC) of 0.67 (95% CI 0.61 to 0.72))
at 6 months' post-diagnosis (Angstman 2017); to predict persistent
symptoms at 6 months (C-statistic not reported; R2 of 0.40 in devel-
opment sample and 0.27 in validation sample) (Rubenstein 2007);
and to predict onset of depression in non-depressed general prac-
tice attendees (C-statistic of 0.79 (95% CI 0.77 to 0.81)) (King 2010).
In a scoping review, only one model was identified to predict risk
of recurrence of depression over three years (C-statistic of 0.72 on
external validation) (Wang 2014). There has been no systematic re-
view to identify all such models.
O B J E C T I V E S
Primary objective
To summarise the predictive performance of prognostic models de-
veloped to predict the risk of relapse, recurrence, sustained remis-
sion or recovery in adults with depression who meet criteria for re-
mission.
Secondary objectives
• To describe the characteristics of models identified, including
predictors and method of derivation (e.g. regression, machine
learning, neural networks etc.).
Prognostic models for predicting relapse or recurrence of depression (Protocol)









Cochrane Database of Systematic Reviews
• To review the net benefit of identified models, where this has
been reported.
• To summarise the value of updating or modifying an existing
prognostic model or identify whether the development of a nov-
el prognostic model to predict relapse and recurrence in depres-
sion is required. We will make this decision through discussion
involving the whole team and will be guided by risk of bias as-
sessment and applicability of methods as well as predictive per-
formance.
Investigation of sources of heterogeneity between
studies
We anticipate between-study heterogeneity in model performance.
Sources of heterogeneity in this case are likely to relate to popula-
tion/case mix (e.g. age of participants and multimorbidity), study
setting of models (e.g. differences between models developed in
primary and secondary care settings), study design (e.g. follow-up
time, source of data, outcome definition and sample size). All of
these could prove to be significant sources of heterogeneity in this
review and we will take them into account in the event that a meta-
analysis is undertaken.
M E T H O D S
Criteria for considering studies for this review
The eligibility criteria required for studies to be included in the re-
view will be informed by the following PICOTS criteria.
• Population — adult patients (18 years and over) diagnosed with
depression and meeting criteria for remission.
• Index model — all prognostic models predicting relapse, recur-
rence, sustained remission or recovery in patients with depres-
sion.
• Comparator — there is no comparator in this review.
• Outcome(s) — relapse, recurrence, sustained remission or re-
covery in depression. We will accept and clearly document any
definition.
• Timing — our pre-specified start-point is the point at which a pa-
tient has responded to treatment and is identified as meeting
criteria for remission. The end-points are those described under
‘Outcome(s)’ over any time period.
• Setting — any setting (primary, secondary or community care).
We will include models developed for participants from high-,
medium- or low-income countries.
Types of studies
We will include all model development and validation (internal and
external) studies, including those that update existing models. If a
sufficient number of external validation studies exist for a particu-
lar model, we will perform a meta-analysis to provide a quantitative
summary of that model’s predictive performance. We will report a
qualitative description of the rationale, methods and outcome of
studies that aimed to update an existing model and we will treat up-
dated models as separate models for the purposes of meta-analy-
sis. We expect the majority of studies to be cohort studies (both
prospective and retrospective; and most likely to include prognosis
studies based on registries and on cohorts from randomised con-
trolled trial data). We will include other types of studies if they meet
the other inclusion criteria. Reports of impact assessments of prog-
nostic models (e.g. in randomised trials) will not be included in this
review, as these studies require different methodology.
Targeted population
Adult patients (18 years and over) who have been diagnosed with
(by validated diagnostic tool or diagnostic interview) and treat-
ed for depression and now meeting criteria for remission. We will
exclude models developed in populations with co-morbid severe
mental illness (for example, schizophrenia and bipolar affective
disorder) as these patients will typically receive more intensive psy-
chiatric input and results would be less generalizable. Children with
depressive disorders are treated in very different settings with dif-
ferent practitioners and follow-up schedules and may have mean-
ingfully different predictors than independent adult patients. We
will include older adults, although we will be mindful that multi-
morbidity may impact on depression outcomes in this population
more so than in a general adult population.
Types of prognostic models
All multivariable prognostic models developed to predict the risk
of relapse, recurrence, sustained remission or recovery in individ-
uals with depression who have entered remission. We will not in-
clude models that predict sustained depressive symptoms as these
models require a different population (i.e. those who have been di-
agnosed as depressed rather than those with depression who have
subsequently entered remission). We are interested in all multivari-
ate models, whether they were developed to guide therapeutic de-
cision-making or for any other purpose. They must have been de-
veloped with this intention of providing individual risk predictions,
and not for other purposes (e.g. to quantify the adjusted effect of
a prognostic factor). Metrics for discrimination or calibration (or
both) should be reported.
Types of outcomes to be predicted
Relapse, recurrence, sustained remission or recovery in depression
over any time period. We will accept all definitions.
Search methods for identification of studies
Electronic searches
An Information Specialist will conduct searches on the follow-
ing bibliographic databases using relevant subject headings (con-
trolled vocabularies) and search syntax, appropriate to each re-
source. The search strategies will be designed to identify prognos-
tic models developed to predict the risk of relapse, recurrence, sus-
tained remission or recovery in adults with (unipolar) depression
who have entered remission.
• Ovid MEDLINE (1946 onwards) (Appendix 1);
• Ovid Embase (1980 onwards);
• Ovid PsycINFO (1806 onwards);
• Cochrane Library (current issue);
• Web of Science (1900 onwards).
We will not request any restrictions on date, language or publica-
tion status be applied to the searches. We will screen the results of
the MEDLINE search in the first instance to help increase the preci-
sion of the search for the target population. We will also consider
the sensitivity and specificity of the prognostic models filter at this
point.
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The Information Specialist will search for retraction statements
and errata once we have selected the included studies and will
rerun all searches close to publication if the initial search date is
greater than 12 months.
Searching other resources
The Information Specialist will search the following sources of grey
literature (primarily for dissertations and theses).
• Open Grey (www.opengrey.eu);
• ProQuest Dissertations & Theses Global (www.pro-
quest.com/products-services/pqdtglobal.html);
• DART-Europe E-theses Portal (www.dart-europe.eu);
• EThOS - the British Libraries e-theses online service
(ethos.bl.uk);
• Open Access Theses and Dissertations (oatd.org).
Reference lists
We will check the reference lists of all relevant study reports and the
Information Specialist will conduct a forward citation search on the
Web of Science and Google Scholar, to identify additional studies
missed from the original electronic searches (e.g. unpublished or
in-press citations).
Personal communication
We will contact authors and subject experts for information on un-
published or ongoing studies, or to request additional data.
Data collection
Selection of studies
Two independent reviewers will review the titles and abstracts of
studies identified by the search strategy and full texts obtained for
studies potentially meeting the inclusion criteria. The two review-
ers will resolve uncertainty or disagreement through discussion or,
if necessary, by referral to a third researcher.
Data extraction and management
Two independent reviewers will conduct the data extraction (ASM
and NM). The Checklist for Critical Appraisal and Data Extraction
for Systematic Reviews of Prediction Modelling Studies (CHARMS)
has been developed to guide data extraction in systematic reviews
of prognostic models and we will use it for this review. Data to be
extracted are:
• method of depression diagnosis;
• year of patient recruitment and follow-up;
• setting;
• source of data;
• participants' characteristics;
• study design;
• definition of relapse and recurrence;
• information on number and type of candidate predictors;
• sample size;
• number of events;
• missing data;
• model development (e.g. logistic regression, Cox regression,
machine learning, neural network) and any adjustment for mod-
el overfitting (e.g. using penalisation or shrinkage techniques);
• model performance (calibration, discrimination and classifica-
tion measures), including optimism-adjusted estimates in the
development data;
• model evaluation (method used, whether internal and external
validation was done, model updating in case of poor validation);
and
• results: interpretation and discussion of generalizability,
strengths and weaknesses
We will also collect information on how the model was presented
(risk chart, nomogram, full regression formula) and whether it is
possible to use a model based on the information presented in the
article. Where measures of predictive performance are not avail-
able directly, we will extract these with reference to recent guid-
ance (Debray 2018).
Assessment of risk of bias in included studies
Two independent reviewers will assess risk of bias using the Predic-
tion model riskof bias assessment tool (PROBAST), which assesses
risk of bias over four domains, as well as applicability (Riley 2019;
Wolff 2019).
• Participants: appropriate data sources and inclusion/exclusion
criteria.
• Predictors: which should be defined and assessed in a similar
way for all participants, assessed without knowledge of out-
comes and available at the time at which the model is intended
for use.
• Outcomes: determined appropriately, pre-specified, predictors
should be excluded from outcome definition, defined and deter-
mined in a similar way for all participants, determined without
knowledge of predictors, and appropriate time interval between
predictor assessment and outcome determination.
• Analysis: reasonable number of participants with the outcome,
appropriate handling of continuous and categorical predic-
tors, all enrolled participants should be included in the analy-
sis, missing data handled appropriately, relevant model per-
formance measures handled appropriately, overfitting and op-
timism in performance accounted for and predictors and as-
signed weights in the final model should correspond to results
from multivariable analysis.
Measures of association or predictive performance measures
to be extracted
We will extract information about the models’ predictive perfor-
mance, in terms of discrimination (C-statistic, area under the curve)
and calibration (calibration slope, OE ratio, calibration plots), and
net benefit measures.
Dealing with missing data
When performance measures (such as C-statistic, OE ratio) are not
reported in the paper, we will contact authors. If we are unable to
obtain the required data, we will use standard methods and formu-
lae described by Debray and colleagues to estimate the O:E ratio
and C-statistic and associated standard errors (Debray 2017). If this
is not possible due to limited data, we will explore the impact of
missing data in a sensitivity analysis.
Prognostic models for predicting relapse or recurrence of depression (Protocol)
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Assessment of heterogeneity
Reviews of prognostic studies often have to deal with a substantial
amount of heterogeneity. We will assess the impact of heterogene-
ity in predictive performance across validation studies, by calculat-
ing prediction intervals which provide a range for the potential per-
formance of a model in a new validation study (Debray 2017). We
will also calculate I2 and Tau2 statistics. We will extract performance
in subgroups if reported.
If there are sufficient data (a minimum of 10 studies), we will investi-
gate potential sources of heterogeneity using meta-regression with
the transformed summary estimate of model performance (e.g.
logit C-statistic or log O:E ratio) as a dependent variable and study-
level covariates (population/case-mix (age of participants and mul-
timorbidity), study setting of models (primary and secondary care
settings) and study design (follow-up time, source of data, outcome
definition and sample size) as explanatory variables.
Data synthesis
Data synthesis and meta-analysis approaches
We will initially complete a narrative data synthesis, reporting the
performance of individual prognostic models. Data are likely to be
highly heterogeneous; therefore, if we identify a sufficient number
of high-quality studies externally validating the same model, a ran-
dom-effects meta-analysis will be performed, aiming to summarise
the performance of that model. If possible we will pool informa-
tion about each model’s discrimination (using C-statistic or equiva-
lent), calibration (using calibration slope, calibration-in-the-large;
and ratio of observed (O) to expected (E) events (O:E ratio)) and
equivalents from time-to-event models (e.g. Harrell’s C-statistic,
calibration slope, D statistic, O:E at each time point). For each per-
formance measure separately, we will use a random-effects meta-
analysis model with transformed performance measures (logit C-
statistic and log O:E ratio) to produce a summary result (with 95%
confidence intervals (CIs)) that quantifies the average performance
across studies. To better account for the uncertainty in the es-
timated between-study heterogeneity, we will use the restricted
maximum likelihood (REML) estimation, with 95% CIs for the sum-
mary (average) performance of a model, derived using the Har-
tung-Knapp-Sidik-Jonkmann method, as recommended by Debray
2017 and Langan 2018.
Subgroup analysis and investigation of heterogeneity
We will investigate for potential sources of heterogeneity using
meta-regression with the transformed summary estimate of mod-
el performance (e.g. logit C-statistic or log O:E ratio) as a depen-
dent variable and study level characteristics as explanatory vari-
ables (see above). This will only be possible if there are a sufficient
number of studies (usually 10 or more). We will evaluate the impact
of risk of bias by doing analyses only of those studies assessed to
be low risk of bias.
Sensitivity analysis
To explore the differences in model performance between prima-
ry and secondary care patients we will perform sensitivity analysis,
looking at the impact of excluding secondary care patients on mod-
el performance. We will also examine effects of missing data and
multimorbidity here if applicable.
Conclusions and summary of findings
We will use the summary of findings to highlight the better perform-
ing models and next steps for their comparison, extension or imple-
mentation. We will consider the benefits of updating and/or exter-
nally validating an existing model with sufficiently reasonable per-
formance, low risk of bias and acceptable applicability or we will
develop a novel model for validation and impact assessment in a
primary care cohort.
A C K N O W L E D G E M E N T S
We thank the Cochrane Prognosis Methods Group for providing
guidance during protocol development; and the editorial team of
the Cochrane Common Mental Disorders (CCMD) Group including
Jessica Hendon (Managing Editor) and Sarah Dawson (Information
Specialist) who helped develop the search strategies.
The authors and the CCMD Editorial Team are grateful to the follow-
ing peer reviewers for their time and comments: Johanna Damen
(Cochrane Prognosis Methods Group), Christopher Dowrick, Karen
Morley and Abhijna Vithal Yergolkar. They would also like to thank
Cochrane Copy Edit Support for the team's help.
The National Institute for Health Research (NIHR) is the largest sin-
gle funder of the CCMD Group.
Andrew Moriarty is funded by a NIHR Doctoral Research Fellowship
for this research project. This publication presents independent re-
search funded by the NIHR. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the De-
partment of Health and Social Care.
Prognostic models for predicting relapse or recurrence of depression (Protocol)









Cochrane Database of Systematic Reviews




Ali S, Rhodes L, Moreea O, McMillan D, Gilbody S, Leach C, et al.
How durable is the effect of low intensity CBT for depression
and anxiety? Remission and relapse in a longitudinal cohort
study. Behaviour Research and Therapy 2017;94:1-8.
Angstman 2017
Angstman KB, Garrison GM, Gonzalez CA, Cozine DW, Cozine EW,
Katzelnick DJ. Prediction of primary care depression outcomes
at six months: validation of DOC-6. Journal of the American
Board of Family Medicine 2017;30(3):281-7.
Beshai 2011
Beshai S, Dobson KS, Bockting CLH, Quigley L. Relapse and
recurrence prevention in depression: current research and
future prospects. Clinical Psychology Review 2011;31(8):1349-60.
Bockting 2015
Bockting CL, Hollon SD, Jarrett RB, Kuyken W, Dobson K.
A lifetime approach to major depressive disorder: The
contributions of psychological interventions in preventing
relapse and recurrence. Clinical Psychology Review
2015;41:16e26.
Buckman 2018
Buckman JE, Underwood A, Clarke K, Saunders R, Hollon SD,
Fearon P, et al. Risk factors for relapse and recurrence of
depression in adults and how they operate: A four-phase
systematic review and meta-synthesis. Clinical Psychology
Review 2018;64:13-38.
Debray 2017
Debray TP, Damen JA, Snell KI, Ensor J, HooH L, Reitsma JB, et
al. A guide to systematic review and meta-analysis of prediction
model performance. BMJ 2017;356:i6460.
Debray 2018
Debray TP, Damen JA, Riley RD, Snell K, Reitsma JB, HooH L, et
al. A framework for meta-analysis of prediction model studies
with binary and time-to-event outcomes. Statistical Methods
in Medical Research 2018 July 23 [Epub ahead of print]. [DOI:
doi.org/10.1177/0962280218785504]
Kendler 2000
Kendler KS, Thornton LM, Gardner CO. Stressful life events and
previous episodes in the etiology of major depression. American
Journal of Psychiatry 2000;157(8):1243-51.
King 2010
King, Walker C, Levy G, Bottomley C, Royston P, Weivh S, et al.
Development and validation of an international risk prediction
algorithm for episodes of major depression in general practice
attendees. Archives of General Psychiatry 2010;65(12):1368-77.
Langan 2018
Langan D, Simmonds M. A comparison of heterogeneity
variance estimators in simulated random - effects meta -
analyses. Research Synthesis Methods 2019;10(1):83-98.
PROGRESS 2013
MRC PROGnosis RESearch Strategy (PROGRESS) Partnership.
PROGRESS series: a framework for prognosis research; 2013.
Available at www.progress-partnership.org.
Riley 2019
Riley RD, van der Windt DPC, Moons K. Prognosis research
in healthcare: concepts, methods, and impact. First Edition.
Oxford University Press, 2019.
Rubenstein 2007
Rubenstein LV, Rayburn NR, Keeler EB, Ford DE, Rost KM,
Sherbourne CD. Predicting outcomes of primary care patients
with major depression: development of a depression prognosis
index. Psychiatric Services 2007;58(8):1049-56.
Wang 2014
Wang JL, Patten S, Sareen J, Bolton J, Schmitz N, MacQueen G.
Development and validation of a prediction algorithm for use
by health professionals in prediction of recurrence of major
depression. Depression and Anxiety 2014;31(5):451-7.
WHO 2018
World Health Organization. Depression. Available at
www.who.int/news-room/fact-sheets/detail/depression.
Wolff 2019
Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M,
Collins GS, et al. PROBAST: A tool to assess the risk of bias and
applicability of prediction model studies. Annals of Internal
Medicine 2019;170(1):51.
 
A P P E N D I C E S
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2 DEPRESSIVE DISORDER/ (70786)
3 DEPRESSIVE DISORDER, MAJOR/ (28163)
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4 DEPRESSION, POSTPARTUM/ (5084)
5 DEPRESSIVE DISORDER, TREATMENT-RESISTANT/ (1064)
6 (depress* adj3 (acute or clinical* or diagnos* or disorder* or major or unipolar or illness or scale* or score* or adult* or patient* or
participant* or people or inpatient* or in-patient* or outpatient* or out-patient*)).ti,ab,kf. (151900)
7 (depress* and (Beck* or BDI* or DSM* or (Statistical Manual adj2 Mental Disorders) or Hamilton or HAM-D or HAMD or MADRS or (Inter-
national Classification adj2 Disease?) or ICD-10 or ICD10 or ICD-9 or ICD9 or PHQ-9 or PHQ9 or patient health questionnaire or GDS or
EPDS)).ab. (47514)
8 "with depressi*".ab. (24930)
9 (depressi* or depressed).ti. (136381)
10 (depress* adj3 (postnatal* or post-natal* or postpartum* or post-partum* or pregnan*)).ti,ab,kf. (7938)
11 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,kf. (11607)
12 (depress* and ((antidepress* or anti-depress* or SSRI* or SNRI* or serotonin or medication* or psychotropic or treatment*) adj2 (fail*
or no* respon* or nonrespon* or non-respon* or unrespon* or un-respon*))).ti,ab,kf. (1516)
13 or/1-12 (293144)
14 (recurr* or relaps* or remiss* or remitt*).ti,ab,kf,hw. (885726)
15 13 and 14 (20248)
16 ((recurr* or reoccur* or re-occur* or new episode or another episode or relaps* or re-emerg* or resurg* or re-surg* or reappear* or re-
appear* or flare-up) adj5 depress*).ti,ab,kf. (5741)
17 ((remiss* or remitt* or recover*) adj5 depress*).ti,ab,kf. (6268)
18 or/15-17 (23629)
19 (Prognosis/ or Decision Support Techniques/) and (Algorithms/ or Logistic Models/ or Risk Assessment/) (44253)
20 ((prognos* or predict* or decision*) and (algorithm? or model* or rule? or risk? or outcome?)).ti,kf,hw. (400284)
21 ((prognos* or predict* or decision*) adj3 (algorith? or model* or rule? or risk? or outcome?)).ab. (244497)
22 clinical prediction.mp. (2467)
23 ((prognos* or predict* or decision*) and (history or variable* or criteria or scor* or characteristic* or finding* or factor*)).ti,kf,hw.
(316814)
24 ((prognos* or predict* or decision*) adj3 (history or variable* or criteria or scor* or characteristic* or finding* or factor*)).ab. (230941)
25 or/19-24 (818040)
26 18 and 25 (2404)
27 (exp animals/ or exp models, animal/) not humans.sh. (4602276)
28 (mice or mouse or murine or rat or rats or rodent* or animal model*).ti. (1408830)
29 26 not (27 or 28) (2399)
30 (comment or letter or editorial or news).sh. (1925773)
31 29 not 30 (2388)
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